Sorafenib and surgery for hepatocellular carcinoma – a controversial relation: Lesson learned?

Sorafenib is a breakthrough in the medical treatment aiming to control hepatocellular carcinoma (HCC) progression, but there some controversy patients' selection. The introduction of has led several positive effects. New more than promising antiangiogenic molecules have followed. Immunotherapy combined with therapy also strongly entered into HCC. All that induced significant guideline revision profiling as second line systemic event advanced However, for those patients resectable HCC, selection surgery or should be reviewed and reconsidered.